SOX in the Boardroom: What the Sarbanes?Oxley Act Means to You

Penny Cass;

Publication

Article

June 15, 2003

BioPharm International

BioPharm International-06-01-2003

Volume16

Issue 6

SOX in the Boardroom: What the Sarbanes?Oxley Act Means to You

Author(s):

Penny Cass

by Penny Cass, BioPharm International Stay current on the changes in corporate governance regulations ? whether your company is public or private, in the United States or elsewhere. As a capital-intensive industry, many of our third-party associations are going to require that biopharmaceutical companies comply with the new regulations to receive financing. The trend to regulate corporate governance activities hasn't ended ? more rules promulgated by more government entities should be anticipated.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Guest Interview: A Strong Dose of Reality: Visiting with Cynthia Robbins-Roth

Collaborating Across the Extended Pharmaceutical Enterprise: How Sharing Information Leads to Process Enablement

Sialylation Levels Influence Oligosaccharide Quantitation: Analyzing Response Variability Using High-pH Anion-Exchange Chromatography and Pulsed Amperometric Detection

SOX in the Boardroom: What the Sarbanes?Oxley Act Means to You

The Project Management Institute's Pharmaceutical Specific Interest Group 2002 Benchmark Survey Results: Project Managers and Project Management in the Biotech Industry

Small Biopharms Face Unique Challenges: Outsourcing in Early-Stage Drug Development

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

SOX in the Boardroom: What the Sarbanes?Oxley Act Means to You

Newsletter